Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Combination Therapy: Placebo + Chemotherapy	46	65
Total, all-cause mortality	Combination Therapy: Farletuzumab + Chemotherapy	39	64
Total, all-cause mortality	Monotherapy: Placebo	1	35
Total, all-cause mortality	Monotherapy: Farletuzumab	0	31
Total, other adverse events	Combination Therapy: Placebo + Chemotherapy	60	65
Total, other adverse events	Combination Therapy: Farletuzumab + Chemotherapy	63	64
Total, other adverse events	Monotherapy: Placebo	30	35
Total, other adverse events	Monotherapy: Farletuzumab	25	31
Total, serious adverse events	Combination Therapy: Placebo + Chemotherapy	27	65
Total, serious adverse events	Combination Therapy: Farletuzumab + Chemotherapy	27	64
Total, serious adverse events	Monotherapy: Placebo	6	35
Total, serious adverse events	Monotherapy: Farletuzumab	7	31

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01218516/event-totals